Angina Pectoris
Pipeline Programs↗
Active Trials↗
Companies Involved↗
Angina Pectoris is a moderately active landscape with 55 programs across 28 companies. The most active players are Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), Shanghai Greenvalley Pharmaceutical Co., Ltd., Amgen. 33 therapies are approved with 3 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
1 program
Shanghai Greenvalley Pharmaceutical Co., Ltd.
1 program
Amgen
2 programs
Wanbangde Pharmaceutical Group Co., LTD
2 programs
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2 programs
Sanofi
2 programs
Pipeline
Programs by Phase
Analysis
Modality Breakdown
97%
Small molecule
67 of 69 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 69 classified programs, each share of the total. Modality classified for 100% of 70 pipeline programs.
Analysis
Trial Status
31
clinical trials
Clinical Trials
Trial Activity
31 trials
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)